Acro Biomedical Co., Ltd. (ACBM)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2022 | -15.87 Million USD | -106.07% |
| 2021 | -7.7 Million USD | -6457.58% |
| 2020 | -117.45 Thousand USD | 68.39% |
| 2019 | -371.6 Thousand USD | -188.55% |
| 2018 | 419.66 Thousand USD | 18768.15% |
| 2017 | -2248.00 USD | 94.82% |
| 2016 | -43.42 Thousand USD | 8.55% |
| 2015 | -47.49 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 Q1 | -4 Million USD | -1.75% |
| 2023 Q2 | -3.19 Million USD | 20.2% |
| 2022 FY | -15.87 Million USD | -106.07% |
| 2022 Q2 | -3.99 Million USD | -1.73% |
| 2022 Q3 | -4.01 Million USD | -0.37% |
| 2022 Q1 | -3.92 Million USD | -1.97% |
| 2022 Q4 | -3.93 Million USD | 1.89% |
| 2021 Q1 | -59.49 Thousand USD | 3.69% |
| 2021 Q2 | -794.68 Thousand USD | -1235.74% |
| 2021 Q3 | -2.99 Million USD | -276.35% |
| 2021 Q4 | -3.85 Million USD | -28.82% |
| 2021 FY | -7.7 Million USD | -6457.58% |
| 2020 Q3 | -73.09 Thousand USD | -14.76% |
| 2020 Q1 | 81.11 Thousand USD | 206.91% |
| 2020 FY | -117.45 Thousand USD | 68.39% |
| 2020 Q4 | -61.77 Thousand USD | 15.5% |
| 2020 Q2 | -63.69 Thousand USD | -178.53% |
| 2019 Q3 | -75.15 Thousand USD | -47.88% |
| 2019 Q1 | -169.75 Thousand USD | -126.29% |
| 2019 FY | -371.6 Thousand USD | -188.55% |
| 2019 Q4 | -75.87 Thousand USD | -0.95% |
| 2019 Q2 | -50.82 Thousand USD | 70.06% |
| 2018 Q4 | -75.01 Thousand USD | -148.82% |
| 2018 FY | 419.66 Thousand USD | 18768.15% |
| 2018 Q3 | 153.67 Thousand USD | 32.12% |
| 2018 Q2 | 116.3 Thousand USD | 67.47% |
| 2018 Q1 | 69.45 Thousand USD | -13.43% |
| 2017 FY | -2248.00 USD | 94.82% |
| 2017 Q1 | -22.44 Thousand USD | -202.75% |
| 2017 Q2 | -11.88 Thousand USD | 47.03% |
| 2017 Q3 | 39.49 Thousand USD | 432.25% |
| 2017 Q4 | 80.22 Thousand USD | 103.13% |
| 2016 FY | -43.42 Thousand USD | 8.55% |
| 2016 Q4 | -7413.00 USD | -20.99% |
| 2016 Q3 | -6127.00 USD | 64.22% |
| 2016 Q2 | -17.12 Thousand USD | -169.69% |
| 2016 Q1 | -6350.00 USD | 54.07% |
| 2015 Q4 | -13.82 Thousand USD | -491.61% |
| 2015 Q2 | -18.00 USD | 37.93% |
| 2015 Q1 | -29.00 USD | 99.94% |
| 2015 FY | -47.49 Thousand USD | 0.0% |
| 2015 Q3 | -2337.00 USD | -12883.33% |
| 2014 Q4 | -45.1 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -1088.488% |
| Arch Therapeutics, Inc. | -6.98 Million USD | -127.292% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 129.958% |
| Nascent Biotech, Inc. | -2.08 Million USD | -660.242% |
| Rebus Holdings, Inc. | -1.02 Million USD | -1456.024% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 124.368% |
| Qrons Inc. | -789.34 Thousand USD | -1910.705% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -2409.688% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 74.646% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -3720.035% |
| Skye Bioscience, Inc. | -37.64 Million USD | 57.839% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 78.828% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | -141.35% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -5705.167% |
| SQZ Biotechnologies Company | -79.46 Million USD | 80.027% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -448.73% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -771.804% |
| Mesoblast Limited | -87.95 Million USD | 81.955% |
| Marizyme, Inc. | -65.34 Million USD | 75.712% |
| Genus plc | 7.9 Million USD | 300.904% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | -45.72% |
| Pharming Group N.V. | -10.54 Million USD | -50.469% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -631.466% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -327.775% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | -79.46% |
| ContraFect Corporation | -65.15 Million USD | 75.64% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | -224.831% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -818.776% |
| IMV Inc. | -36.48 Million USD | 56.5% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | -96.924% |
| MultiCell Technologies, Inc. | -380.07 USD | -4175826.277% |
| ONE Bio Corp. | 8.67 Million USD | 282.922% |
| Accustem Sciences Inc. | -3.74 Million USD | -323.643% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 69.296% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -1152.547% |
| Q BioMed Inc. | -2.05 Million USD | -673.427% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -325.166% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -566.624% |
| Biomind Labs Inc. | -1.21 Million USD | -1207.024% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 73.426% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -411.69% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | -100.826% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -714.234% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -105879.187% |
| Curative Biotechnology, Inc. | -5.81 Million USD | -172.834% |
| GB Sciences, Inc. | -1.36 Million USD | -1065.581% |
| Alpha Cognition Inc. | -13.77 Million USD | -15.24% |
| HST Global, Inc. | -146.21 Thousand USD | -10755.238% |
| CSL Limited | 2.64 Billion USD | 100.601% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -804.474% |
| Halberd Corporation | -79.67 Thousand USD | -19819.98% |
| Enzolytics Inc. | -2.17 Million USD | -629.107% |
| Agentix Corp. | -1.37 Million USD | -1054.949% |
| Resverlogix Corp. | -3.61 Million USD | -339.652% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -400.45% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 94.621% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 16295.35% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 329.204% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -299.483% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -424.479% |
| AVAX Technologies, Inc. | -6.41 Million USD | -147.464% |
| Zenith Capital Corp. | -10.59 Million USD | -49.787% |
| Genscript Biotech Corporation | -95.47 Million USD | 83.377% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -68187.768% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -282.819% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -26159.568% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -691.548% |
| Kadimastem Ltd | -3.3 Million USD | -379.877% |
| Helix BioMedix, Inc. | -1.05 Million USD | -1402.896% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | -315.592% |
| BioStem Technologies, Inc. | -8.48 Million USD | -87.097% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -3495.958% |
| LadRx Corporation | 400.44 Thousand USD | 4063.471% |
| Cell Source, Inc. | -5.32 Million USD | -198.267% |
| Regen BioPharma, Inc. | 1.02 Million USD | 1650.691% |
| Regen BioPharma, Inc. | 1.02 Million USD | 1650.691% |
| NovAccess Global Inc. | -4.76 Million USD | -232.791% |
| Affymax, Inc. | -14.42 Million USD | -10.035% |
| Itoco Inc. | -1.86 Million USD | -749.197% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | -257.261% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -850.955% |
| Mobile Lads Corp. | -2.26 Million USD | -601.255% |
| CytoDyn Inc. | -49.84 Million USD | 68.156% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -19982.045% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -6857.284% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -1585.709% |
| SYBLEU INC | -180.3 Thousand USD | -8702.602% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -884.131% |
| International Stem Cell Corporation | -131 Thousand USD | -12015.605% |
| Bioxytran, Inc. | -4.28 Million USD | -270.828% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -29144.257% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -527.269% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 66.984% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -650.778% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -1932.489% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -400.993% |
| Neutra Corp. | -233.46 Thousand USD | -6698.211% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 21.781% |
| PureTech Health plc | -65.69 Million USD | 75.841% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 25.369% |
| IXICO plc | -1.17 Million USD | -1247.321% |
| IntelGenx Technologies Corp. | -9.92 Million USD | -59.882% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 72.218% |
| CSL Limited | 2.64 Billion USD | 100.601% |
| Cellectis S.A. | -103.17 Million USD | 84.617% |